Aardvark therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

San diego, july 18, 2025 (globe newswire) -- aardvark therapeutics, inc. (aardvark) (nasdaq: aard), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that between july 8-14, 2025, two new employees were granted inducement awards consisting of stock options to purchase an aggregate of 10,372 shares of common stock.
AARD Ratings Summary
AARD Quant Ranking